Background: Erectile dysfunction [ED] is the inability to obtain and maintain an erection appropriate for sexual activity. estimated one in ten adult males experience ED on a long-term basis.
Aim of the work: We aimed to assess endothelial biomarkers [C-reactive protein and fibrinogen] before and after Platelet-Rich Plasma versus daily Tadalafil 5 mg and evaluate the role of Platelet-Rich Plasma in vasculogenic erectile dysfunction.
Patients and Methods: This research had been conducted on 40 cases with vasculogenic ED and 10 normal healthy individuals as a control. Patients were divided into two groups; group 1 which included 20 ED patients who received daily Tadalafil 5 mg, and group 2 which included 20 ED patients who were injected with Platelet-Rich Plasma. CRP and Fibrinogen were collected from all patients before and after treatment.
Results: The findings in this study supported that Tadalafil has a higher value in treatment in male patients with ED. As regards the Peak systolic velocity [PSV], it significantly increased from 17±1.07 cm/s before tadalafil treatment to 27.37±1.24cm/s after it [P value = 0.04]. Also, it was significantly increased in the PRP group from 13±1.02 cm/s at the baseline to 25.37±1.33 cm/s after it [P value = 0.013]. The difference between the two groups at the baseline was significant statistically [P value = 0.03] [Table 2], however after treatment we found no statistically significant difference between the 2 groups [P value = 0.1].
Conclusion: According to our results, Tadalafil and PRP improve the inflammatory biomarkers such as CRP and Fibrinogen, although the increase of the biomarkers was more in Tadalafil, Tadalafil is more effective than PRP in the therapy of men with Erectile Dysfunction.